Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 9/20 | 0.42 |
| ▸ | TAB1 | Q15750 | 9/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284829 | 0.79 | PDPK1 (0.52) | PDPK1TTBK1TTBK2 | |
| SCHEMBL12270784 | 0.79 | MAP3K7 (0.50) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL9682496 | 0.78 | CDK2 (0.59) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL2940695 | 0.77 | PDPK1 (0.36) | PDPK1LRRK2 | |
| SCHEMBL3388862 | 0.76 | KDM4E (0.40) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL2623129 | 0.76 | CDK1 (0.50) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL16549309 | 0.75 | CDK2 (0.41) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL17924977 | 0.72 | PDPK1 (0.34) | PDPK1 | |
| SCHEMBL22639807 | 0.72 | CDK1 (0.48) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL2938606 | 0.72 | MAP3K7 (0.37) | MAP3K7TAB1KDM4EPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5574149-A | Method of treating HIV infections with 2',3'-dideoxy-3'-fluoro-5-chlorouridine | GLAXO WELLCOME INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0586523-A4 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | UNIV YALE (US) | 1995-11-29 | — | — | EP | disclosed |
| EP-0670328-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-06 | — | — | EP | disclosed |
| EP-0669341-A1 | Therapeutic Nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-30 | — | — | EP | disclosed |
| EP-0586523-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0317128-A2 | Anti-HIV Pyrimidine Nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-24 | — | — | EP | disclosed |